|
LETTER TO SHAREHOLDERS
September 22, 2008
Dear Shareholders:
We are very pleased to report a number of extremely
positive developments regarding subsidiary Live Tissue
Connect (LTC), in response to a number of calls from
shareholders regarding progress since beginning the
U.S. LTC surgical device commercialization process two
years ago.
In February 2007 we reported moving forward on developing
the Live Tissue Connect commercial electrogenerator
and instruments. We started to organize the LTC U.S.
infrastructure, interview executive personnel and prepared
to file for U.S. FDA 510(k) clearance and European CE
Mark certification.
Since then we have achieved and completed a number
of very key developments and implemented proactive strategies,
including the following major milestones:
- Hired internationally recognized and highly experienced
medical industry expert as president of LTC Technologies
division.
- Hired an outstanding staff of dedicated key design and
software engineers, regulatory staff, marketing executives
and support staff.
- Opened LTC offices in Goleta, CA (Santa Barbara).
- Added a medical advisory board of internationally recognized
surgeons.
- Developed a relationship with Stellartech one of the leading
designers of electrosurgey generators to design and manufacture
our VAD 400 electrosurgery generator for commercial distribution.
- Contracted with Ventrex to manufacture our LTC disposable
instruments.
- Purchased assets and hired key design engineers and regulatory
experts from ViR a well-known instrument design company;
LTC now has its own in-house disposable instrumentation
design capability.
- Added a technical advisory board of leading medical device
engineers and experts.
- Presented papers at three international medical conferences.
- We have 31 issued or pending patents worldwide.
- We have identified and completed in Ukraine over 80 surgical
procedures that the LTC technology can perform, and the
Ukraine surgeons have performed over 10,000 human surgeries
in Ukraine hospitals using the prototype technology.
- Developed our LTC electrosurgery generator and two instruments,
and importantly, have a pipeline of several new instruments
in development.
- LTC has received its ISO 13485:2003 certification for
the design and manufacture of Bipolar Forceps Systems.
- In July received U.S. FDA 510(k) clearance for the LTC
VAD 400 electrosurgery generator and two instruments.
- Last month, we received CE Mark certification for the
VAD 400 and instruments.
- Established six divisions in LTC, each being positioned
for license and distribution opportunities. These divisions
are: General/GYN- Colon Rectal- Pulmonary- Arthroscopy-
Urology- Aesthetics
- Currently building inventories and negotiating with distributors
so LTC can enter the commercial markets in January 2009
On the environmentally friendly CleanTech side:
- CSMG recently purchased Carbon Capture Technologies,
Inc. (CCTI) which included the worldwide rights to a
new state-of-the-art CO2 removal technology developed
at the University of Ottawa, Canada.
- We believe this technology uniquely positions CSMG to
enter the CO2 removal business for coal fired utility
plant’s stack gas emissions.
Since July 2006 we have received and invested over
$7 million in Live Tissue Connect, raised by our investment
banker, Jessup & Lamont Securities Corporation.
We believe the LTC tissue-welding technology has the
ability to revolutionize the $3.5 billion a year surgical
procedure market.
We believe, based upon the above milestones, CSMG International
(OTCBB: CTGI
- News) is at a major turning point in
terms of revenue generation and corporate expansion.
Sincerely,
Donald S. Robbins
Sign up to receive CSMG Technologies automated email
press releases and other notifications: Please go to:
www.csmgtechinternational.com/contact_information.html
and fill-in information.
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
CONTACT:
CSMG Technologies, Inc.
Donald S. Robbins, 361-887-7546
President and CEO
or
K. Bruce Jones, 770-955-0409
Newsletter Archive:
August 7, 2008
June 30, 2008
May 20, 2008
September 19, 2007
November 29, 2006
August 3, 2006
February 16, 2006
|
